Stress ulcer prophylaxis is commonly administered to critically ill patients for the prevention of clinically important stress-related mucosal bleeding from the upper gastrointestinal tract. Despite widespread incorporation of stress ulcer prophylaxis into practice around the world, questions are emerging about its indications and impact. This clinically focused article will review current controversies related to stress ulcer prophylaxis for critically ill adult patients, including bleeding frequency, risk factors, comparative efficacy, adverse effect profile, and overall cost-effectiveness of the available stress ulcer prophylaxis regimens.
A MEDLINE search was conducted from inception through August 2015.
Selected publications describing stress ulcer prophylaxis in adult patients were retrieved (original research, systematic reviews, and practice guidelines); their bibliographies were also reviewed to identify additional pertinent publications.
Data from relevant publications were abstracted and summarized.
The existing evidence is organized to describe the patients most likely to benefit from stress ulcer prophylaxis, review the comparative efficacy of proton pump inhibitors and histamine 2 receptor antagonists, the adverse effects of stress ulcer prophylaxis, and overall cost-effectiveness.
Many stress ulcer prophylaxis recommendations are based on older studies at risk of bias, which may not be applicable to modern practice. Stress ulcer prophylaxis should be limited to patients considered to be at high risk for clinically important bleeding. When evaluating only the trials at low risk for bias, the evidence does not clearly support lower bleeding rates with proton pump inhibitors over histamine 2 receptor antagonists; however, proton pump inhibitors appear to be the dominant drug class used worldwide today. The current rate of upper gastrointestinal bleeding and the relative adverse effects of acid suppression on infectious risk may drive not only the effectiveness, but also the cost-effectiveness of stress ulcer prophylaxis today. Research is currently underway to better address these issues.
1Department of Pharmacy Practice, Midwestern University, College of Pharmacy-Glendale, Glendale, AZ.
2Division of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, TX.
3Department of Pharmacy, Banner-University Medical Center-Phoenix, Phoenix AZ.
4Departments of Medicine and Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada.
Dr. Barletta received funding from Hospira and Cubist Pharmaceuticals (he is a consultant for Hospira and Cubist Pharmaceuticals). He disclosed off-label product use: histamine-2-receptor antagonists and proton pump inhibitors for the indication of stress ulcer prophylaxis. Dr. Bruno disclosed off-label product use: use of proton pump inhibitors and H2-receptor antagonists for stress ulcer prophylaxis in the critically ill. Only select agents in each of these classes are Food and Drug Administration approved for this indication; the majority are not. Dr. Cook’s institution received funding from Physicians Services of Ontario. Dr. Buckley disclosed that he does not have any potential conflicts of interest. All of the authors have been investigators on the topic of stress ulcer prophylaxis.
For information regarding this article, E-mail: firstname.lastname@example.org